People not taking Paxlovid experienced the viral rebound phenomenon only about two per cent of the time, the researchers at the Mass General Brigham hospital, Boston, US, found. Paxlovid, which is a Nirmatrelvir-ritonavir therapy taken orally, has been previously studied to be effective in reducing hospitalisation and death in severe COVID-19 infections.